JP2018502558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502558A5 JP2018502558A5 JP2017526550A JP2017526550A JP2018502558A5 JP 2018502558 A5 JP2018502558 A5 JP 2018502558A5 JP 2017526550 A JP2017526550 A JP 2017526550A JP 2017526550 A JP2017526550 A JP 2017526550A JP 2018502558 A5 JP2018502558 A5 JP 2018502558A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antibody
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 174
- 150000007523 nucleic acids Chemical class 0.000 claims description 97
- 108020004707 nucleic acids Proteins 0.000 claims description 91
- 102000039446 nucleic acids Human genes 0.000 claims description 91
- 102000013498 tau Proteins Human genes 0.000 claims description 79
- 108010026424 tau Proteins Proteins 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 48
- 150000001413 amino acids Chemical group 0.000 claims description 45
- 239000003112 inhibitor Substances 0.000 claims description 44
- 208000034799 Tauopathies Diseases 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 39
- 229940124597 therapeutic agent Drugs 0.000 claims description 31
- 208000024827 Alzheimer disease Diseases 0.000 claims description 30
- 108060003951 Immunoglobulin Proteins 0.000 claims description 28
- 102000018358 immunoglobulin Human genes 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 20
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 16
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 16
- 239000003540 gamma secretase inhibitor Substances 0.000 claims description 16
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 15
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 claims description 14
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims description 14
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 14
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 14
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 14
- 239000002738 chelating agent Substances 0.000 claims description 13
- 230000033616 DNA repair Effects 0.000 claims description 12
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 11
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 11
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 9
- 230000006933 amyloid-beta aggregation Effects 0.000 claims description 9
- 230000004064 dysfunction Effects 0.000 claims description 9
- 239000002955 immunomodulating agent Substances 0.000 claims description 9
- 229940044551 receptor antagonist Drugs 0.000 claims description 9
- 239000002464 receptor antagonist Substances 0.000 claims description 9
- 229940124648 γ-Secretase Modulator Drugs 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 8
- 229960004640 memantine Drugs 0.000 claims description 8
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 8
- 239000002184 metal Substances 0.000 claims description 8
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 7
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 229950001863 bapineuzumab Drugs 0.000 claims description 7
- 239000002439 beta secretase inhibitor Substances 0.000 claims description 7
- 229960003530 donepezil Drugs 0.000 claims description 7
- 229960003980 galantamine Drugs 0.000 claims description 7
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 7
- 239000002858 neurotransmitter agent Substances 0.000 claims description 7
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 claims description 7
- 229960004136 rivastigmine Drugs 0.000 claims description 7
- 229950007874 solanezumab Drugs 0.000 claims description 7
- 229960001685 tacrine Drugs 0.000 claims description 7
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 7
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims description 6
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims description 6
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- 229950002508 gantenerumab Drugs 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 5
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 5
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 5
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 claims description 5
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 5
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 5
- 230000002529 anti-mitochondrial effect Effects 0.000 claims description 5
- 239000003524 antilipemic agent Substances 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 230000006951 hyperphosphorylation Effects 0.000 claims description 5
- 229940127121 immunoconjugate Drugs 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 5
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims description 5
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims description 5
- 229960004633 pirenzepine Drugs 0.000 claims description 5
- 229910052723 transition metal Inorganic materials 0.000 claims description 5
- 150000003624 transition metals Chemical class 0.000 claims description 5
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims description 4
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 claims description 4
- 229940126077 BACE inhibitor Drugs 0.000 claims description 4
- 108091007911 GSKs Proteins 0.000 claims description 4
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 102000004895 Lipoproteins Human genes 0.000 claims description 4
- 108090001030 Lipoproteins Proteins 0.000 claims description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 4
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 4
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003324 growth hormone secretagogue Substances 0.000 claims description 4
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 4
- 239000003149 muscarinic antagonist Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 229960003570 tramiprosate Drugs 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 102000057063 human MAPT Human genes 0.000 claims description 3
- 229940072221 immunoglobulins Drugs 0.000 claims description 3
- -1 tramiprostate Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 230000001906 cholesterol absorption Effects 0.000 claims 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 239000013589 supplement Substances 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 40
- 239000002773 nucleotide Substances 0.000 description 28
- 125000003729 nucleotide group Chemical group 0.000 description 28
- 238000009396 hybridization Methods 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 7
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000019771 cognition Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 229950003486 ponezumab Drugs 0.000 description 4
- 229940122777 Tau aggregation inhibitor Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 229940121649 protein inhibitor Drugs 0.000 description 3
- 239000012268 protein inhibitor Substances 0.000 description 3
- 239000003909 protein kinase inhibitor Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 2
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 2
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 2
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 238000012879 PET imaging Methods 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 108010011562 aspartic acid receptor Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000002469 receptor inverse agonist Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081809P | 2014-11-19 | 2014-11-19 | |
| US62/081,809 | 2014-11-19 | ||
| PCT/IB2015/002610 WO2016079597A1 (en) | 2014-11-19 | 2015-11-18 | Humanized tau antibodies in alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020047903A Division JP6864763B2 (ja) | 2014-11-19 | 2020-03-18 | アルツハイマー病におけるヒト化タウ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502558A JP2018502558A (ja) | 2018-02-01 |
| JP2018502558A5 true JP2018502558A5 (enExample) | 2018-12-27 |
| JP6830061B2 JP6830061B2 (ja) | 2021-02-17 |
Family
ID=55411706
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526550A Active JP6830061B2 (ja) | 2014-11-19 | 2015-11-18 | アルツハイマー病におけるヒト化タウ抗体 |
| JP2020047903A Active JP6864763B2 (ja) | 2014-11-19 | 2020-03-18 | アルツハイマー病におけるヒト化タウ抗体 |
| JP2021063583A Pending JP2021119774A (ja) | 2014-11-19 | 2021-04-02 | アルツハイマー病におけるヒト化タウ抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020047903A Active JP6864763B2 (ja) | 2014-11-19 | 2020-03-18 | アルツハイマー病におけるヒト化タウ抗体 |
| JP2021063583A Pending JP2021119774A (ja) | 2014-11-19 | 2021-04-02 | アルツハイマー病におけるヒト化タウ抗体 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10160799B2 (enExample) |
| EP (2) | EP3221349B1 (enExample) |
| JP (3) | JP6830061B2 (enExample) |
| KR (1) | KR20170126855A (enExample) |
| CN (1) | CN107428820B (enExample) |
| AU (2) | AU2015348012B2 (enExample) |
| BR (1) | BR112017010498A2 (enExample) |
| CA (1) | CA2966964A1 (enExample) |
| CY (1) | CY1123746T1 (enExample) |
| DK (1) | DK3221349T3 (enExample) |
| ES (1) | ES2848376T3 (enExample) |
| HR (1) | HRP20210124T1 (enExample) |
| HU (1) | HUE053239T2 (enExample) |
| IL (2) | IL251921B (enExample) |
| LT (1) | LT3221349T (enExample) |
| MX (2) | MX388142B (enExample) |
| PL (1) | PL3221349T3 (enExample) |
| PT (1) | PT3221349T (enExample) |
| RS (1) | RS61431B1 (enExample) |
| RU (2) | RU2730668C2 (enExample) |
| SG (1) | SG11201703237VA (enExample) |
| SI (1) | SI3221349T1 (enExample) |
| SM (1) | SMT202100055T1 (enExample) |
| WO (1) | WO2016079597A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201707855YA (en) | 2013-03-13 | 2017-10-30 | Prothena Biosciences Ltd | Tau immunotherapy |
| SG10202007103TA (en) | 2014-11-05 | 2020-09-29 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| SI3221349T1 (sl) * | 2014-11-19 | 2021-02-26 | Axon Neuroscience Se | Humanizirano tau protitelo pri alzheimerjevi bolezni |
| JP7481726B2 (ja) | 2016-05-02 | 2024-05-13 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| PE20190208A1 (es) * | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| PL3452507T3 (pl) | 2016-05-02 | 2023-01-09 | Prothena Biosciences Limited | Immunoterapia tau |
| SG11201907422RA (en) * | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| WO2018178077A1 (en) * | 2017-03-28 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| PE20200695A1 (es) | 2017-05-02 | 2020-06-16 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| WO2019048017A1 (en) * | 2017-09-07 | 2019-03-14 | Danmarks Tekniske Universitet | METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND |
| UA129617C2 (uk) | 2017-10-16 | 2025-06-18 | Еісаі Р Енд Д Менеджмент Ко., Лтд. | Антитіло до тау та його застосування |
| NZ766453A (en) | 2018-02-01 | 2022-02-25 | Nkmax Co Ltd | Method of producing natural killer cells and composition for treating cancer |
| US12398201B2 (en) | 2018-02-19 | 2025-08-26 | New York University | Tau single domain antibodies |
| AU2019244481A1 (en) | 2018-03-28 | 2020-10-01 | Axon Neuroscience Se | Antibody-based methods of detecting and treating Alzheimer's disease |
| EP3788062A4 (en) * | 2018-05-03 | 2022-02-16 | Washington University | Methods of diagnosing and treating based on site-specific tau phosphorylation |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| US20210347869A1 (en) * | 2018-10-17 | 2021-11-11 | The University Of Queensland | Methods and compositions for treating tauopathies |
| AU2019377595A1 (en) * | 2018-11-08 | 2021-05-27 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN113544149B (zh) | 2019-03-03 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| WO2021030615A1 (en) * | 2019-08-13 | 2021-02-18 | Washington University | Methods to detect mtbr tau isoforms and use thereof |
| US20220402979A1 (en) | 2019-09-09 | 2022-12-22 | Axon Neuroscience Se | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
| MX2022002880A (es) | 2019-09-10 | 2022-03-25 | Washington University St Louis | Ensayo basado en sangre para diagnosticar y tratar fosforilacion de tau especifica con base en el sitio. |
| JP2023506014A (ja) * | 2019-12-12 | 2023-02-14 | アレクトル エルエルシー | 抗ｃｄ３３抗体の使用方法 |
| US20230201136A1 (en) * | 2020-02-28 | 2023-06-29 | Genemo, Inc. | Methods and materials for diagnosis and treatment of neuronal disorder |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| US20230364104A1 (en) * | 2020-09-22 | 2023-11-16 | Kathleen E. Clarence-Smith | Pharmaceutical combination for the treatment of human hypocholinergic disorders |
| CN113156134B (zh) * | 2020-11-26 | 2024-01-23 | 江苏荃信生物医药股份有限公司 | 用于检测人白介素23的elisa试剂盒及检测方法 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2024036005A1 (en) * | 2022-08-10 | 2024-02-15 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| AU2023342086A1 (en) | 2022-09-15 | 2025-03-13 | Voyager Therapeutics, Inc. | Tau binding compounds |
| CA3237624A1 (en) * | 2023-07-28 | 2025-04-24 | Genentech, Inc. | NEW USES FOR OMALIZUMAB |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2026005695A1 (en) * | 2024-06-25 | 2026-01-02 | Islam Tohidul | Detection of oligomeric tau and soluble tau aggregates |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HU196394B (en) | 1986-06-27 | 1988-11-28 | Richter Gedeon Vegyeszet | Process for preparing 2-halogenated ergoline derivatives |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| JPH07509250A (ja) | 1992-07-27 | 1995-10-12 | アメリカ合衆国 | 血液脳バリヤーへのリポソームの標的化 |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| CA2142190C (fr) | 1995-02-14 | 1998-01-27 | Marc Lessard | Conduite d'exfiltration d'air use |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| DK2275119T3 (da) | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| DK0994728T3 (da) | 1997-04-09 | 2008-12-01 | Intellect Neurosciences Inc | Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DE60028055D1 (de) | 1999-09-09 | 2006-06-22 | Max Planck Gesellschaft | Screening nach inhibitoren von "gepaarten helikalen filamenten" |
| EP1257584B2 (en) | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| KR20100018071A (ko) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| EP1521774B1 (en) | 2002-07-12 | 2008-08-27 | Axon Neuroscience Forschungs- und Entwicklungs Gmbh | Truncated tau proteins |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| CA2791165C (en) | 2002-12-03 | 2015-02-24 | Blanchette Rockefeller Neurosciences Institute | A conjugate comprising cholesterol linked to tetracycline |
| MXPA05006940A (es) | 2002-12-24 | 2006-02-22 | Neurochem Int Ltd | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. |
| US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
| DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| BR112013008333B1 (pt) * | 2010-10-07 | 2022-10-11 | Ac Immune S.A. | Anticorpo, composição farmacêutica, hibridoma, polinucleotídeo, método de diagnóstico in vitro e usos do anticorpo |
| MX345092B (es) * | 2010-10-11 | 2017-01-17 | Univ Zuerich | Anticuerpos anti-tau humanos,. |
| CN109265543B (zh) | 2011-09-19 | 2022-04-26 | 阿克松神经系统科学公司 | 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断 |
| WO2013151762A1 (en) * | 2012-04-05 | 2013-10-10 | Ac Immune S.A. | Humanized tau antibody |
| ES2816700T3 (es) * | 2012-12-21 | 2021-04-05 | Biogen Ma Inc | Anticuerpos anti-tau humanos |
| SI3221349T1 (sl) * | 2014-11-19 | 2021-02-26 | Axon Neuroscience Se | Humanizirano tau protitelo pri alzheimerjevi bolezni |
-
2015
- 2015-11-18 SI SI201531480T patent/SI3221349T1/sl unknown
- 2015-11-18 RU RU2017120688A patent/RU2730668C2/ru active
- 2015-11-18 HU HUE15837211A patent/HUE053239T2/hu unknown
- 2015-11-18 AU AU2015348012A patent/AU2015348012B2/en active Active
- 2015-11-18 CN CN201580072454.2A patent/CN107428820B/zh active Active
- 2015-11-18 HR HRP20210124TT patent/HRP20210124T1/hr unknown
- 2015-11-18 PT PT158372110T patent/PT3221349T/pt unknown
- 2015-11-18 SM SM20210055T patent/SMT202100055T1/it unknown
- 2015-11-18 ES ES15837211T patent/ES2848376T3/es active Active
- 2015-11-18 WO PCT/IB2015/002610 patent/WO2016079597A1/en not_active Ceased
- 2015-11-18 EP EP15837211.0A patent/EP3221349B1/en active Active
- 2015-11-18 KR KR1020177016640A patent/KR20170126855A/ko not_active Ceased
- 2015-11-18 BR BR112017010498A patent/BR112017010498A2/pt not_active Application Discontinuation
- 2015-11-18 EP EP20198475.4A patent/EP3786182A1/en active Pending
- 2015-11-18 US US15/528,333 patent/US10160799B2/en active Active
- 2015-11-18 MX MX2017006663A patent/MX388142B/es unknown
- 2015-11-18 LT LTEP15837211.0T patent/LT3221349T/lt unknown
- 2015-11-18 JP JP2017526550A patent/JP6830061B2/ja active Active
- 2015-11-18 CA CA2966964A patent/CA2966964A1/en not_active Abandoned
- 2015-11-18 PL PL15837211T patent/PL3221349T3/pl unknown
- 2015-11-18 RS RS20210132A patent/RS61431B1/sr unknown
- 2015-11-18 RU RU2020126237A patent/RU2020126237A/ru unknown
- 2015-11-18 DK DK15837211.0T patent/DK3221349T3/da active
- 2015-11-18 SG SG11201703237VA patent/SG11201703237VA/en unknown
-
2017
- 2017-04-25 IL IL251921A patent/IL251921B/en unknown
- 2017-05-19 MX MX2021014367A patent/MX2021014367A/es unknown
-
2018
- 2018-11-05 US US16/181,088 patent/US10745469B2/en active Active
-
2020
- 2020-03-18 JP JP2020047903A patent/JP6864763B2/ja active Active
- 2020-07-10 US US16/926,062 patent/US11319363B2/en active Active
- 2020-08-31 AU AU2020227007A patent/AU2020227007B2/en active Active
-
2021
- 2021-01-11 CY CY20211100012T patent/CY1123746T1/el unknown
- 2021-04-02 JP JP2021063583A patent/JP2021119774A/ja active Pending
- 2021-06-21 IL IL284250A patent/IL284250A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502558A5 (enExample) | ||
| RU2017120688A (ru) | Гуманизированные тау-антитела при болезни альцгеймера | |
| JP6952221B2 (ja) | コイルドコイルの免疫グロブリン融合タンパク質およびその組成物 | |
| JP7587304B2 (ja) | タウ認識抗体 | |
| AU2009245354B2 (en) | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof | |
| JP2020141669A5 (enExample) | ||
| JP7481726B2 (ja) | タウ認識抗体 | |
| JP7194985B2 (ja) | タウ認識抗体 | |
| US20130108641A1 (en) | Anti-gitr antibodies | |
| JP2025063136A (ja) | タウ認識抗体 | |
| CA3119072A1 (en) | Antibodies recognizing tau | |
| HK40121102A (zh) | 识别tau的抗体 | |
| HK1137182B (en) | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |